GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:007135312 | Prostate | Tumor | cellular response to interleukin-4 | 13/3246 | 33/18723 | 2.26e-03 | 1.28e-02 | 13 |
GO:003106011 | Prostate | Tumor | regulation of histone methylation | 22/3246 | 69/18723 | 2.31e-03 | 1.30e-02 | 22 |
GO:004240111 | Prostate | Tumor | cellular biogenic amine biosynthetic process | 14/3246 | 37/18723 | 2.43e-03 | 1.36e-02 | 14 |
GO:004663411 | Prostate | Tumor | regulation of alpha-beta T cell activation | 30/3246 | 104/18723 | 2.48e-03 | 1.38e-02 | 30 |
GO:004853811 | Prostate | Tumor | thymus development | 16/3246 | 45/18723 | 2.59e-03 | 1.43e-02 | 16 |
GO:007200913 | Prostate | Tumor | nephron epithelium development | 31/3246 | 109/18723 | 2.70e-03 | 1.48e-02 | 31 |
GO:004352315 | Prostate | Tumor | regulation of neuron apoptotic process | 53/3246 | 212/18723 | 2.92e-03 | 1.58e-02 | 53 |
GO:004561911 | Prostate | Tumor | regulation of lymphocyte differentiation | 45/3246 | 174/18723 | 2.93e-03 | 1.58e-02 | 45 |
GO:000300711 | Prostate | Tumor | heart morphogenesis | 60/3246 | 246/18723 | 2.99e-03 | 1.61e-02 | 60 |
GO:004663111 | Prostate | Tumor | alpha-beta T cell activation | 41/3246 | 156/18723 | 3.21e-03 | 1.68e-02 | 41 |
GO:000930911 | Prostate | Tumor | amine biosynthetic process | 14/3246 | 38/18723 | 3.24e-03 | 1.69e-02 | 14 |
GO:190210712 | Prostate | Tumor | positive regulation of leukocyte differentiation | 41/3246 | 157/18723 | 3.63e-03 | 1.86e-02 | 41 |
GO:190370812 | Prostate | Tumor | positive regulation of hemopoiesis | 41/3246 | 157/18723 | 3.63e-03 | 1.86e-02 | 41 |
GO:000165612 | Prostate | Tumor | metanephros development | 25/3246 | 85/18723 | 4.12e-03 | 2.08e-02 | 25 |
GO:00323501 | Prostate | Tumor | regulation of hormone metabolic process | 13/3246 | 35/18723 | 4.14e-03 | 2.08e-02 | 13 |
GO:000320611 | Prostate | Tumor | cardiac chamber morphogenesis | 33/3246 | 121/18723 | 4.16e-03 | 2.09e-02 | 33 |
GO:000327911 | Prostate | Tumor | cardiac septum development | 29/3246 | 103/18723 | 4.26e-03 | 2.13e-02 | 29 |
GO:003021711 | Prostate | Tumor | T cell differentiation | 61/3246 | 257/18723 | 5.30e-03 | 2.54e-02 | 61 |
GO:000165712 | Prostate | Tumor | ureteric bud development | 26/3246 | 91/18723 | 5.32e-03 | 2.54e-02 | 26 |
GO:007208013 | Prostate | Tumor | nephron tubule development | 26/3246 | 91/18723 | 5.32e-03 | 2.54e-02 | 26 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa046597 | Prostate | BPH | Th17 cell differentiation | 36/1718 | 108/8465 | 9.75e-04 | 4.47e-03 | 2.76e-03 | 36 |
hsa0492814 | Prostate | BPH | Parathyroid hormone synthesis, secretion and action | 33/1718 | 106/8465 | 5.30e-03 | 1.75e-02 | 1.08e-02 | 33 |
hsa0465912 | Prostate | BPH | Th17 cell differentiation | 36/1718 | 108/8465 | 9.75e-04 | 4.47e-03 | 2.76e-03 | 36 |
hsa0492815 | Prostate | BPH | Parathyroid hormone synthesis, secretion and action | 33/1718 | 106/8465 | 5.30e-03 | 1.75e-02 | 1.08e-02 | 33 |
hsa0465922 | Prostate | Tumor | Th17 cell differentiation | 36/1791 | 108/8465 | 2.11e-03 | 8.42e-03 | 5.22e-03 | 36 |
hsa0492822 | Prostate | Tumor | Parathyroid hormone synthesis, secretion and action | 35/1791 | 106/8465 | 2.89e-03 | 1.07e-02 | 6.67e-03 | 35 |
hsa0465932 | Prostate | Tumor | Th17 cell differentiation | 36/1791 | 108/8465 | 2.11e-03 | 8.42e-03 | 5.22e-03 | 36 |
hsa0492832 | Prostate | Tumor | Parathyroid hormone synthesis, secretion and action | 35/1791 | 106/8465 | 2.89e-03 | 1.07e-02 | 6.67e-03 | 35 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
GATA3 | SNV | Missense_Mutation | | c.881T>A | p.Met294Lys | p.M294K | P23771 | protein_coding | deleterious(0) | possibly_damaging(0.692) | TCGA-5L-AAT1-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | letrozol | SD |
GATA3 | SNV | Missense_Mutation | | c.1095N>T | p.Arg365Ser | p.R365S | P23771 | protein_coding | deleterious(0.04) | probably_damaging(1) | TCGA-AR-A0U2-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | tamoxiphen | PD |
GATA3 | SNV | Missense_Mutation | | c.983N>A | p.Leu328His | p.L328H | P23771 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AR-A24P-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
GATA3 | SNV | Missense_Mutation | novel | c.989G>A | p.Arg330Lys | p.R330K | P23771 | protein_coding | deleterious(0.01) | probably_damaging(1) | TCGA-B6-A40C-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | cyclophosphamide | SD |
GATA3 | SNV | Missense_Mutation | | c.1071G>T | p.Met357Ile | p.M357I | P23771 | protein_coding | deleterious(0.01) | probably_damaging(0.925) | TCGA-BH-A0BQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
GATA3 | SNV | Missense_Mutation | novel | c.992N>A | p.Arg331Lys | p.R331K | P23771 | protein_coding | deleterious(0.04) | probably_damaging(0.946) | TCGA-BH-A0C7-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | CR |
GATA3 | SNV | Missense_Mutation | | c.881N>A | p.Met294Lys | p.M294K | P23771 | protein_coding | deleterious(0) | possibly_damaging(0.692) | TCGA-BH-A0H5-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | CR |
GATA3 | SNV | Missense_Mutation | | c.845N>G | p.His282Arg | p.H282R | P23771 | protein_coding | deleterious(0) | possibly_damaging(0.882) | TCGA-BH-A0HF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
GATA3 | SNV | Missense_Mutation | | c.881N>A | p.Met294Lys | p.M294K | P23771 | protein_coding | deleterious(0) | possibly_damaging(0.692) | TCGA-BH-A0HP-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | doxorubicin | SD |
GATA3 | SNV | Missense_Mutation | | c.356A>T | p.Lys119Met | p.K119M | P23771 | protein_coding | deleterious(0) | probably_damaging(0.936) | TCGA-BH-A18M-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
2625 | GATA3 | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR | | mercaptopurine | MERCAPTOPURINE | 24141364 |
2625 | GATA3 | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR | | pegaspargase | PEGASPARGASE | 24141364 |
2625 | GATA3 | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR | | leucovorin | LEUCOVORIN | 24141364 |
2625 | GATA3 | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR | | vincristine | VINCRISTINE | 24141364 |
2625 | GATA3 | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR | | thioguanine | THIOGUANINE | 24141364 |
2625 | GATA3 | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR | | asparaginase | ASPARAGINASE | 24141364 |
2625 | GATA3 | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR | | prednisone | PREDNISONE | 24141364 |
2625 | GATA3 | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR | | methotrexate | METHOTREXATE | 24141364 |
2625 | GATA3 | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR | | dexamethasone | DEXAMETHASONE | 24141364 |
2625 | GATA3 | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR | | doxorubicin | DOXORUBICIN | 24141364 |